Who owns Enliven Therapeutics Inc (ELVN)? Superinvestor holders
2 superinvestors of the 157 tracked here hold Enliven Therapeutics Inc (ELVN) in their latest 13F filing, with $53.3M between them. Doug Silverman gives it the most weight: 0.28% of the reported portfolio. In their latest reported quarter, Doug Silverman opened a position.
Ron Baron sold out of it in their latest quarter.
Key facts
- Superinvestors holding it
- 2 of 157
- Biggest holder
- Julian and Felix Baker, $45.9M
- Largest weight
- Doug Silverman, 0.28%of their portfolio
- Combined value
- $53.3M
- Bought last quarter
- 1
- Sold last quarter
- 1
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Doug SilvermanSenator Investment Group | 0.28% | $7.3M | 160K | New | +160K | Q3 2026 |
| 2 | Julian and Felix BakerBaker Bros. Advisors | 0.23% | $45.9M | 905.19K | No change | 0 | Q2 2026 |
Sold out last quarter
- Ron Baronwas $380.6K · Q3 2026
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 1 | 160K | $7.3M | 1 | 1 |
| Q2 2026 | 157 | 1 | 905.19K | $45.9M | 0 | 0 |
| Q1 2026 | 157 | 1 | 905.19K | $35.5M | 1 | 0 |
| Q4 2025 | 157 | 1 | 271.41K | $4.2M | 1 | 1 |
| Q3 2025 | 157 | 2 | 1.06M | $21.7M | 1 | 1 |
| Q2 2025 | 157 | 3 | 1.43M | $28.6M | 1 | 0 |
| Q1 2025 | 156 | 2 | 963.82K | $19M | 0 | 0 |
| Q4 2024 | 156 | 2 | 963.82K | $21.7M | 0 | 1 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Doug Silverman | 160K | — | — | — | — | — | — | — |
| Julian and Felix Baker | · | 905.19K | 905.19K | 271.41K | 114.83K | 114.83K | 114.83K | 114.83K |
| Stanley Druckenmiller | · | — | — | — | 947.41K | 463K | — | — |
| Peter Kolchinsky | · | — | — | — | — | 848.99K | 848.99K | 848.99K |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own ELVN?
In their latest 13F filings: Doug Silverman (0.28% of the portfolio, $7.3M), Julian and Felix Baker (0.23% of the portfolio, $45.9M).
Who bought ELVN last quarter?
Doug Silverman (new position). “Last quarter” is each investor's latest reported quarter.
Who sold ELVN last quarter?
Sold out entirely: Ron Baron (was $380.6K).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns Enliven Therapeutics Inc (ELVN)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/ELVN/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to ELVN by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.